Genetics

New hybrid whale-dolphin discovered in Hawaii

Last year, a team of scientists spotted what they believed was a hybrid animal off the coast of Kauai, Hawaii.A new report from Cascadia Research Collectiveconfirms they did and the new sea creature is the result of a whale and a dolphin mating, the teams head researcher told CBS News.

What the researchers discovered was a hybrid of a melon-headed whale and a rough-toothed dolphin. In an interview with local newspaperThe Garden Island,the head of the project said the discovery is their most unusual finding. We had the photos and suspected it was a hybrid from morphological characteristics intermediate between species, Robin Baird said.

During their two-week project, scientists were able to get a biopsy sample from the creature and study its genetics. They were able to confirm that the animal was a hybrid. Based on the genetics, the father was a rough-toothed dolphin and the mother a melon-headed whale, Baird told CBS News via email.

One of the species that makes up this hybrid is very rare in Hawaii. Melon-headed whales usually dont swim in these waters, so when scientists spotted the whale, they put satellite tags on the animal. During this two-week study, scientists also spotted another rare species in the water, pantropical spotted dolphins, which they also tagged.

Bairds research team is going to be back in Kauais waters next month, when they hope to get more photos of the new hybrid whale-dolphin and water samples. They also hope to do testing on other species in the area.

Were hoping that just by talking to some tour operators and fishermen we might get tips and encounter something like pilot whales, Baird said.

More here:
New hybrid whale-dolphin discovered in Hawaii

Genetics

LR hospital hires cancer institute chief – arkansasonline.com

The outgoing director of the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences has accepted a job at CHI St. Vincent.

Dr. Peter Emanuel turned in his resignation letter on May 4. His last day at UAMS is Tuesday.

Emanuel, 59, will join CHI St. Vincent on Sept. 1, according to a statement from the hospital. His position was not specified.

At the time of his resignation, he declined to give the reason for his departure, only citing unspecified challenges. He could not be reached for comment Friday afternoon.

UAMS is conducting a national search for a new cancer institute director, said Leslie Taylor, vice chancellor of communications and marketing. Dr. Laura Hutchins was appointed interim director in June. Hutchins is a professor in the College of Medicine Division of Hematology/Oncology, where she was division director from 1998 until September 2013.

Emanuel is a widely recognized expert in leukemia and lymphoma, a UAMS website states. He joined UAMS in 2007 after leaving the University of Alabama at Birmingham, where he was a professor of medicine, genetics and biochemistry.

From 2004 to 2006 he was the acting director of the National Cancer Institute-designated Comprehensive Cancer Center at the Alabama university.

During his time at UAMS, he oversaw the addition of the cancer institute's 12-story research and treatment tower, which opened in 2010. His annual salary was $500,000.

His resignation in May followed UAMS' decision to temporarily suspend its cardiac surgery program due to lead surgeon Dr. Gareth Tobler's retirement. That program restarted at the beginning of July, with the hospital contracting with four new physicians.

UAMS also laid off almost 260 employees in January to curb an anticipated $72.3 million deficit. Those layoffs included one full-time physician -- a general ear, nose and throat doctor who did not work at the cancer institute.

News of Emanuel's new role comes one day after an invoice that his wife, Carla Emanuel, sent seeking reimbursement from the Winthrop P. Rockefeller Cancer Institute became public.

The $4,000 bill lists events that she attended, phone calls she made and work she did to resolve problems with donors. Taylor said UAMS was not going to pay the bill because state procedures regarding vendors and invoices were not followed.

Taylor added that the invoice was the first one she was aware of from a spouse, and the institution does not normally reimburse people for attending fundraising events.

The Arkansas Times first reported on the invoice on Thursday.

Metro on 07/28/2018

See the article here:
LR hospital hires cancer institute chief - arkansasonline.com

Genetics

The Genetics Of Becoming An Ant Queen – sciencefriday.com

Clonal raider ants carrying and grooming larvae. Ants were tagged with colored dots to allow for behavioral observation. Credit: Daniel Kronauer

Many ant species have a queen, the member of the colony that lays eggs. The rest of the ants are divided into different roles that support the queen and the colony. So what ants become queens versus workers? Scientists found that the gene ilp2 that regulates insulin played a role in determining what ant becomes the queen. Their results were published in the journal Science.

[What is the origin of the word quark? Well, let us tell you the tale of particle physics, Aristotle, and James Joyce]

Biologist Ingrid Fetter-Pruneda, an author on that study, talks about how this gene works in determining a queen and what this can tell us about the evolution of societies in insects and beyond.

Continued here:
The Genetics Of Becoming An Ant Queen - sciencefriday.com

Genetics

TOday’s Movers: Seattle Genetics (NASDAQ:SGEN) Stock …

July 27, 2018 - By Vernon Prom

Investors sentiment increased to 1.61 in Q1 2018. Its up 0.38, from 1.23 in 2017Q4. It is positive, as 24 investors sold Seattle Genetics, Inc. shares while 53 reduced holdings. 31 funds opened positions while 93 raised stakes. 159.52 million shares or 12.47% more from 141.83 million shares in 2017Q4 were reported.

California State Teachers Retirement System reported 165,312 shares. 13,084 are held by Bluecrest Cap Ltd. Pictet Asset invested in 0.1% or 786,323 shares. Swiss Bankshares owns 0.02% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 349,100 shares. Keybank National Association Oh invested in 0% or 8,414 shares. 4,998 were accumulated by Shell Asset Mngmt Company. Pnc Financial holds 6,727 shares. Utah Retirement Sys holds 0.02% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) for 19,600 shares. Wells Fargo And Co Mn, a California-based fund reported 306,681 shares. The Connecticut-based Bridgewater Associate L P has invested 0.01% in Seattle Genetics, Inc. (NASDAQ:SGEN). Amundi Pioneer Asset Management has 21,523 shares. National Bank Of America Corp De accumulated 496,573 shares. Daiwa Securities accumulated 4,395 shares. Zurcher Kantonalbank (Zurich Cantonalbank), Switzerland-based fund reported 23,953 shares. Pub Employees Retirement Association Of Colorado invested in 20,183 shares or 0.01% of the stock.

Since February 1, 2018, it had 3 buys, and 12 sales for $266.62 million activity. Cline Darren S also sold $497,983 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) shares. The insider SIEGALL CLAY B sold 18,832 shares worth $951,393. The insider HIMES VAUGHN B sold 5,000 shares worth $290,604. 10,457 shares were sold by DRACHMAN JONATHAN G, worth $552,452.

JP Morgan now has a $77 target on the $11.55 billion market cap company or 5.51 % upside potential. In analysts note issued to clients on Friday, 27 July, Seattle Genetics (NASDAQ:SGEN) shares have had their Overweight Rating kept by professional analysts at JP Morgan.

Among 8 analysts covering Seattle Genetics (NASDAQ:SGEN), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Seattle Genetics has $77.0 highest and $60.0 lowest target. $68.13s average target is -6.65% below currents $72.98 stock price. Seattle Genetics had 12 analyst reports since January 31, 2018 according to SRatingsIntel. SunTrust maintained it with Hold rating and $60.0 target in Wednesday, February 7 report. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned Buy rating by Needham on Wednesday, February 7. J.P. Morgan upgraded the shares of SGEN in report on Wednesday, February 14 to Buy rating. The rating was maintained by Morgan Stanley on Wednesday, March 21 with Overweight. The firm has Buy rating by RBC Capital Markets given on Tuesday, March 20. The firm has Buy rating given on Monday, June 11 by SunTrust. The company was maintained on Wednesday, February 7 by H.C. Wainwright. On Thursday, February 1 the stock rating was maintained by H.C. Wainwright with Buy. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has Neutral rating given on Wednesday, February 7 by Bank of America. The firm has Overweight rating by JP Morgan given on Wednesday, February 14.

The stock increased 2.43% or $1.73 during the last trading session, reaching $72.98. About 1.60M shares traded or 72.55% up from the average. Seattle Genetics, Inc. (NASDAQ:SGEN) has declined 15.50% since July 28, 2017 and is downtrending. It has underperformed by 28.07% the S&P500.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. The company has market cap of $11.55 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. It currently has negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

More notable recent Seattle Genetics, Inc. (NASDAQ:SGEN) news were published by: Streetinsider.com which released: Seattle Genetics (SGEN) Adcetris On-going Launch in 1L cHL is Positive Says SunTrust. on July 02, 2018, also Benzinga.com with their article: Benzingas Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold published on July 26, 2018, Seekingalpha.com published: Mid-stage study underway for Seattle Genetics tisotumab vedotin in solid tumors; shares up 1% premarket on July 12, 2018. More interesting news about Seattle Genetics, Inc. (NASDAQ:SGEN) were released by: Seekingalpha.com and their article: Dont Sell Axon Enterprise Cramers Lightning Round (7/11/18) published on July 12, 2018 as well as Benzinga.coms news article titled: Benzingas Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgens Beat-And-Raise Quarter with publication date: July 27, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Go here to read the rest:
TOday's Movers: Seattle Genetics (NASDAQ:SGEN) Stock ...

Genetics

Seattle Genetics (SGEN) "Buy" Rating Reaffirmed Today By H …

July 27, 2018 - By Mona Holcomb

Investors sentiment increased to 1.61 in Q1 2018. Its up 0.38, from 1.23 in 2017Q4. It is positive, as 24 investors sold Seattle Genetics, Inc. shares while 53 reduced holdings. 31 funds opened positions while 93 raised stakes. 159.52 million shares or 12.47% more from 141.83 million shares in 2017Q4 were reported.

Pub Employees Retirement Association Of Colorado holds 20,183 shares. Jgp Global Gestao De Recursos Ltda reported 22,334 shares or 0.47% of all its holdings. Jane Street Gru Limited Company invested in 3,903 shares or 0% of the stock. Prudential Fincl, New Jersey-based fund reported 6,451 shares. 7,900 were reported by Ellington Management Grp. Caisse De Depot Et Placement Du Quebec reported 5,300 shares or 0% of all its holdings. D E Shaw & stated it has 168,554 shares. Td Asset owns 0.01% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 154,016 shares. Virtu Fincl Ltd Liability Corporation reported 10,922 shares stake. Stratos Wealth Limited holds 0% of its portfolio in Seattle Genetics, Inc. (NASDAQ:SGEN) for 1,213 shares. World Asset Inc stated it has 3,870 shares. State Of Alaska Department Of Revenue reported 9,710 shares stake. Franklin Res has 108,400 shares for 0% of their portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) owns 23,953 shares. 205,300 are owned by California Pub Employees Retirement.

Since February 1, 2018, it had 3 insider buys, and 12 insider sales for $266.62 million activity. $936,818 worth of stock was sold by SIEGALL CLAY B on Friday, February 9. On Thursday, March 15 HIMES VAUGHN B sold $290,604 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) or 5,000 shares. On Wednesday, May 9 the insider Cline Darren S sold $497,983. DRACHMAN JONATHAN G sold $552,452 worth of stock or 10,457 shares.

EU: In an analyst report issued to investors and clients on 27 July, H.C. Wainwright reiterated their Buy rating on Seattle Genetics (SGEN) shares. They now have a $98.0 target price on the firm. H.C. Wainwrights target indicates a potential upside of 37.54 % from the companys last price.

The stock increased 2.04% or $1.45 during the last trading session, reaching $72.7. About 995,861 shares traded or 7.56% up from the average. Seattle Genetics, Inc. (SGEN) has declined 15.50% since July 27, 2017 and is downtrending. It has underperformed by 28.07% the S&P500.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. The company has market cap of $11.50 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. It currently has negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

More notable recent Seattle Genetics, Inc. (NASDAQ:SGEN) news were published by: Streetinsider.com which released: Seattle Genetics (SGEN) Adcetris On-going Launch in 1L cHL is Positive Says SunTrust. on July 02, 2018, also Seekingalpha.com with their article: Dont Sell Axon Enterprise Cramers Lightning Round (7/11/18) published on July 12, 2018, Seekingalpha.com published: Mid-stage study underway for Seattle Genetics tisotumab vedotin in solid tumors; shares up 1% premarket on July 12, 2018. More interesting news about Seattle Genetics, Inc. (NASDAQ:SGEN) were released by: Benzinga.com and their article: Benzingas Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold published on July 26, 2018 as well as Benzinga.coms news article titled: Benzingas Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgens Beat-And-Raise Quarter with publication date: July 27, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read the original:
Seattle Genetics (SGEN) "Buy" Rating Reaffirmed Today By H ...

Immunology

Journal of Investigational Allergology and Clinical Immunology

The Journal of Investigational Allergology and Clinical Immunology (J Investig Allergol Clin Immunol) provides an attractive and very active forum for basic and clinical research in allergology and clinical immunology. The journal publishes original works, reviews, short communications and opinions. It is the Official Journal ofthe Spanish Society of Allergology and Clinical Immunology (SEAIC). The journal will appear bimonthly (6 issues each year). The peer-review system, based on a team of internationally renowned and committed editors, guarantees the scientific quality of the papers.

2018; volume 28, Issue 3more issues

Dupilumab: A New Paradigm for the Treatment of Allergic DiseasesSastre J, Dvila I[summary] [PDF full-Text] Continual Medical Education (1.3 credits)

Alerglogica 2015: A National Survey on Allergic Diseases in the Adult Spanish PopulationOjeda P, Sastre J, Olaguibel JM, Chivato T, On behalf of the investigators participating in the National Survey of the Spanish Society of Allergology and Clinical Immunology Alergolgica 2015[summary] [PDF full-Text]

GLCCI1 Polymorphism rs37973 and Response to Treatment of Asthma With Inhaled CorticosteroidsRijavec M, avbi M, Lopert A, Flear M, Koroec P[summary] [PDF full-Text]

Circulating Helper T-Cell Subsets and Regulatory T Cells in Patients With Common Variable Immunodeficiency Without Known Monogenic DiseaseAzizi G, Mirshafiey A, Abolhassani H, Yazdani R, Jafarnezhad-Ansariha F, Shaghaghi M, Mortazavi-Jahromi SS, Noorbakhsh F, Rezaei N, Aghamohammadi A[summary] [PDF full-Text] [Supplemental Materials]

Common Proteins Located in Pigeon, Budgerigar, and Hen Droppings Related to Bird Fanciers LungRouzet A, Valot B, Reboux G, Millon L, Roussel S[summary] [PDF full-Text]

Fixed Drug Eruption Due to LorazepamAgull-Garca A, Garcs Sotillos M, Cols Sanz C[summary] [PDF full-Text]

Effects of Ole e 1 on Human Bronchial Epithelial Cells Cultured at the Air-Liquid InterfaceLpez-Rodrguez JC, Sols-Fernndez G, Barderas R, Villalba M, Batanero E[summary] [PDF full-Text] [Supplemental Materials]

Resolution of Type IV Hypersensitivity After Bone Marrow TransplantationLzaro M, Vzquez L, Laffond E, Moreno E, Macias EM, Dvila I[summary] [PDF full-Text]

Eosinophilic Esophagitis: Treatment With Different Doses of Omeprazole in Children Under 16 YearsGmez Torrijos E, Donado Palencia P, Sanchez Miranda MP, Moreno Lozano L, Extremera Ortega AM, Borja Segade JM, Galindo Bonilla PA, Garca Rodrguez R[summary] [PDF full-Text]

Prevalence of Clonal Mast Cell Disorders in Patients Presenting With Hymenoptera Venom Anaphylaxis Might Be Higher Than ExpectedVzquez-Revuelta P, Gonzlez-de-Olano D[summary] [PDF full-Text]

Prevalence of Severe Atopic Dermatitis in Adults in 3 Areas of SpainSicras-Mainar A, Navarro-Artieda R, Snchez L, Sastre J[summary] [PDF full-Text]

A Case of Work-Related Donkey Milk AllergyGiorgis V, Rolla G, Raie A, Geuna M, Boita M, Lamberti C, Nebbia S, Giribaldi M, Giuffrida MG, Brussino L, Corradi F, Bacco B, Gallo Cassarino S, Nicola S, Cavallarin L[summary] [PDF full-Text] [Supplemental Materials]

Cutaneous Pseudolymphoma Secondary to Exogenous Pigment in a Polychrome TattooMendez Diaz Y, Garca-Arpa M, Parra Cubillos A, De Lara Simn IM, Garca Rodriguez R, Gmez Torrijos E[summary] [PDF full-Text]

Delayed Hypersensitivity Reaction to Oral Dimethyl FumarateAntolin-Amerigo D, Snchez-Gonzlez MJ, Barbarroja- Escudero J, Ayuso-Peralta L, Belln-Heredia T, Ortega- Berruezo MA, Alvarez-Mon M, Rodrguez-Rodrguez M[summary] [PDF full-Text]

Late Diagnosis of Anaphylactic Reaction to Gadolinium-Based Contrast Media by Skin Tests 10 Years After OnsetHarr T, Jandus P[summary] [PDF full-Text]

Hymenoptera Venom Immunotherapy: How to Safely Switch to the Same Venom From a Different ManufacturerBil MB, Martini M, Berra D, Scarpa A, Losappio L, Quercia O, Lodi Rizzini F, Bignardi D, Cortellini G, Zisa G, Del Giudice A, Manzotti G, Marcotulli C, Murzilli F, Cilia M, Pravettoni V, Borrelli P, Pastorello EA[summary] [PDF full-Text]

Urticaria Induced by Ingestion of Anemonia sulcataDe Aramburu Mera T, Labella lvarez M, Baynova K, Bartolom Zavala B, Prados Castao M[summary] [PDF full-Text]

Blood Eosinophils, Fraction of Exhaled Nitric Oxide, and Serum Eosinophil Cationic Protein as Surrogate Markers for Sputum Eosinophils in Asthma: Influence of Treatment With Inhaled CorticosteroidsAlvarez Puebla MJ, Aroabarren Aleman E, Corcuera Garcia A, Ibaez Bereiz B, Iraola Iribar A, Olaguibel Rivera JM[summary] [PDF full-Text]

Epidemiological Study of the Allergic Population in the North of Gran CanariaSurez-Lorenzo I, Cruz-Niesvaara D, Rodrguez-Gallego C, Rodrguez de Castro F, Carrillo-Diaz T[summary] [PDF full-Text]

New Books

[summary] [PDF full-Text]

See the original post here:
Journal of Investigational Allergology and Clinical Immunology

Biochemistry

Biochemistry | Academic Programs – SUNY Oswego

Biochemistry is the study of chemical components of living creatures from viruses to mammals to explain how and why chemical reactions happen.

Biochemists explore the molecular nature of cells, study the development of illnesses, search for new drugs, predict undeveloped/inherited health problems and help forensic experts identify criminals. Our undergraduate curriculum includes chemistry, mathematics, physics, genetics and biology. Accredited by the American Chemical Society and placed in the top three in the number of certified degrees award in New York, our biochemistry degree will help you pursue graduate study, attend health-related professional schools, or work in entry-level positions at laboratories or in pharmaceutical and biotechnology industries.

Read more:
Biochemistry | Academic Programs - SUNY Oswego

Anatomy

PracticeAnatomy.com – review human anatomy in pictures

PracticeAnatomy.com - review human anatomy in pictures

{"data": [{"identifier": "origin", "item_id": 6795, "id": 241, "lang": "en", "display_priority": 10.0, "name": "Origins", "type": "relation", "active": true, "object_type": "fc_category"}, {"identifier": "nerve", "item_id": 6796, "id": 245, "lang": "en", "display_priority": 40.0, "name": "Nerve supply", "type": "relation", "active": true, "object_type": "fc_category"}, {"identifier": "branch_artery", "item_id": 12237, "id": 391, "lang": "en", "display_priority": 10.0, "name": "Artery branching", "type": "relation", "active": true, "object_type": "fc_category"}, {"identifier": "cranialfossa", "item_id": 9566, "id": 386, "lang": "en", "display_priority": 0.0, "name": "Cranial fossa", "type": "subrelation", "active": true, "object_type": "fc_category"}, {"identifier": "vessels", "item_id": 9235, "id": 354, "lang": "en", "display_priority": 0.0, "name": "Vessels", "type": "subrelation", "active": true, "object_type": "fc_category"}, {"identifier": "tributary_transitive", "item_id": 9584, "id": 387, "lang": "en", "display_priority": 80.0, "name": "Veins", "type": "relation", "active": true, "object_type": "fc_category"}, {"identifier": "premium-demo", "item_id": 9423, "id": 364, "lang": "en", "display_priority": 0.0, "name": "Premium Demo", "type": null, "active": true, "object_type": "fc_category"}, {"identifier": "05", "item_id": 781, "id": 51, "lang": "en", "display_priority": 5.0, "name": "Digestive system", "type": "system", "active": true, "object_type": "fc_category"}, {"identifier": "08", "item_id": 782, "id": 53, "lang": "en", "display_priority": 8.0, "name": "Genital system", "type": "system", "active": true, "object_type": "fc_category"}, {"identifier": "09", "item_id": 3205, "id": 85, "lang": "en", "display_priority": 9.0, "name": "Heart and blood vessels", "type": "system", "active": true, "object_type": "fc_category"}, {"identifier": "demo", "item_id": 9424, "id": 369, "lang": "en", "display_priority": 0.0, "name": "Premium Demo", "type": null, "active": true, "object_type": "fc_category"}, {"identifier": "images", "item_id": 6599, "id": 235, "lang": "en", "display_priority": 0.0, "name": "Terms in images", "type": "super", "active": true, "object_type": "fc_category"}, {"identifier": "02", "item_id": 774, "id": 37, "lang": "en", "display_priority": 2.0, "name": "Bones", "type": "system", "active": true, "object_type": "fc_category"}, {"identifier": "action", "item_id": 6799, "id": 257, "lang": "en", "display_priority": 50.0, "name": "Actions", "type": "relation", "active": true, "object_type": "fc_category"}, {"identifier": "03", "item_id": 775, "id": 39, "lang": "en", "display_priority": 3.0, "name": "Joints", "type": "system", "active": true, "object_type": "fc_category"}, {"identifier": "01", "item_id": 777, "id": 43, "lang": "en", "display_priority": 1.0, "name": "General anatomy", "type": "system", "active": true, "object_type": "fc_category"}, {"identifier": "06", "item_id": 778, "id": 45, "lang": "en", "display_priority": 6.0, "name": "Respiratory system", "type": "system", "active": true, "object_type": "fc_category"}, {"identifier": "07", "item_id": 779, "id": 47, "lang": "en", "display_priority": 7.0, "name": "Urinary system", "type": "system", "active": true, "object_type": "fc_category"}, {"identifier": "04", "item_id": 780, "id": 49, "lang": "en", "display_priority": 4.0, "name": "Muscles", "type": "system", "active": true, "object_type": "fc_category"}, {"identifier": "insertion", "item_id": 6798, "id": 253, "lang": "en", "display_priority": 20.0, "name": "Insertions", "type": "relation", "active": true, "object_type": "fc_category"}, {"identifier": "relations", "item_id": 6797, "id": 249, "lang": "en", "display_priority": 0.0, "name": "Relations", "type": "super", "active": true, "object_type": "fc_category"}, {"identifier": "Hb", "item_id": 790, "id": 69, "lang": "en", "display_priority": 200.0, "name": "Head - Brain", "type": "location", "active": true, "object_type": "fc_category"}, {"identifier": "Hf", "item_id": 791, "id": 71, "lang": "en", "display_priority": 100.0, "name": "Head - Face", "type": "location", "active": true, "object_type": "fc_category"}, {"identifier": "A", "item_id": 788, "id": 65, "lang": "en", "display_priority": 600.0, "name": "Abdomen", "type": "location", "active": true, "object_type": "fc_category"}, {"identifier": "B", "item_id": 787, "id": 63, "lang": "en", "display_priority": 700.0, "name": "Back", "type": "location", "active": true, "object_type": "fc_category"}, {"identifier": "N", "item_id": 784, "id": 57, "lang": "en", "display_priority": 300.0, "name": "Neck", "type": "location", "active": true, "object_type": "fc_category"}, {"identifier": "P", "item_id": 786, "id": 61, "lang": "en", "display_priority": 800.0, "name": "Pelvis", "type": "location", "active": true, "object_type": "fc_category"}, {"identifier": "LE", "item_id": 776, "id": 41, "lang": "en", "display_priority": 900.0, "name": "Lower Extremity", "type": "location", "active": true, "object_type": "fc_category"}, {"identifier": "artery", "item_id": 6800, "id": 261, "lang": "en", "display_priority": 30.0, "name": "Arterial supply", "type": "relation", "active": true, "object_type": "fc_category"}, {"identifier": "antagonist", "item_id": 6801, "id": 265, "lang": "en", "display_priority": 60.0, "name": "Antagonists", "type": "relation", "active": true, "object_type": "fc_category"}, {"identifier": "T", "item_id": 789, "id": 67, "lang": "en", "display_priority": 500.0, "name": "Thorax", "type": "location", "active": true, "object_type": "fc_category"}, {"identifier": "11", "item_id": 3206, "id": 87, "lang": "en", "display_priority": 11.0, "name": "Peripheral nervous system", "type": "system", "active": true, "object_type": "fc_category"}, {"identifier": "10", "item_id": 3207, "id": 89, "lang": "en", "display_priority": 10.0, "name": "Lymphatic and immune system", "type": "system", "active": true, "object_type": "fc_category"}, {"identifier": "13", "item_id": 3208, "id": 91, "lang": "en", "display_priority": 13.0, "name": "Sense and skin", "type": "system", "active": true, "object_type": "fc_category"}, {"identifier": "12", "item_id": 3209, "id": 93, "lang": "en", "display_priority": 12.0, "name": "Central nervous system", "type": "system", "active": true, "object_type": "fc_category"}, {"identifier": "15", "item_id": 3210, "id": 95, "lang": "en", "display_priority": 15.0, "name": "Topography", "type": "system", "active": true, "object_type": "fc_category"}, {"identifier": "foramina", "item_id": 9543, "id": 381, "lang": "en", "display_priority": 70.0, "name": "Foramina", "type": "relation", "active": true, "object_type": "fc_category"}, {"identifier": "UE", "item_id": 783, "id": 55, "lang": "en", "display_priority": 400.0, "name": "Upper Extremity", "type": "location", "active": true, "object_type": "fc_category"}, {"identifier": "nerves", "item_id": 9236, "id": 358, "lang": "en", "display_priority": 0.0, "name": "Nerves", "type": "subrelation", "active": true, "object_type": "fc_category"}, {"identifier": "bone", "item_id": 9237, "id": 362, "lang": "en", "display_priority": 0.0, "name": "Bones", "type": "subrelation", "active": true, "object_type": "fc_category"}]}

Skull Hearth Brain

Practice medical anatomy with personalized questions.

Me si vybrat, co chce procviovat. Obrzky jsou setzeny podle orgnovho systmu a zkladnho umstn na tle.

Um pojmenovat zvraznn sval? Um na obrzku najt zadanou strukturu? Po odpovdi se okamit dozv sprvnou odpov.

Cvienm a opakovnm rostou Tvoje znalosti anatomie. V pehledu znalost vid, co Ti jde dobe a co je poteba jet procviovat.

Pehledn anatomick schmata z spn uebnice Memorix Anatomie. Obrzky byly vybrny tak, aby reprezentovaly zkladn znalosti, kter mohou bt u student medicny vyadovny u zkouky z anatomie.

Dky tomu, e m aplikace uloen odpovdi od vech uivatel, kte ji pouili ped Tebou, me vyhodnotit, kter struktury jsou obecn lehk a kter tk. Dky tomu m aplikace ji po nkolika Tvch odpovdch slunou pedstavu jak dobr jsou Tvoje znalosti anatomie a adekvtn tomu volit dal otzky. Tvoje znalosti Ti um aplikace ukzat na kadm obrzku pomoc obarven jednotlivch st barvami na kle od erven po zelenou.

Systm sleduje, jak Ti anatomie jde, a podle toho vybr dal otzky. Pokud hned zvld i tk otzky, nem smysl T dlouho zdrovat s jednoduchmi. Kdy ale m problmy i s jednoduchmi, aplikace se nebude poutt hned do tkch. Obtnost otzek se tak pizpsobuje Tvm vdomostem.

Read this article:
PracticeAnatomy.com - review human anatomy in pictures

Neuroscience

Neuroscience | Drew University

The neuroscience major at Drew is a multidisciplinary program of study that allows students to explore the brain from the perspectives of many different disciplines, including anthropology, biology, chemistry, computer science, mathematics, physics, philosophy and psychology. After building a firm background in biology, psychology and chemistry, majors study neuroscience topics at more advanced levels. In biology, students tease apart the function of genes and molecules in the brain, investigate how neurons connect with each other in physiological systems and networks that provide the physical substrate for both our conscious and subconscious experiences, and explore animal behavior from an evolutionary viewpoint. In psychology, students look at the anatomical basis of behavior, and examine the data and theory of learning, memory, sensation, perception, language, motivation, reasoning, and creativity.

Explore the pharmacology of drugs designed to treat mental illnesses. Examine how a machine can be programmed to be able to process language and engage in visual perception in a computer science course.

One area of strength in Drews neuroscience program is its employment of laboratory and research experiences. Drews technologically sophisticated neuroscience laboratories are designed to give students broad access to applied experiences in studying the brain. All majors take laboratory courses in which they image live neurons with fluorescent microscopy, measure brain chemicals in animals, and examine changes in brain morphology due to drug exposure, and use computers to study neuroanatomy and neurophysiology and for data collection, statistical analysis and graphic presentations.

All members of the Neuroscience Program have active research programs and work with students on research projects throughout the year.

See the rest here:
Neuroscience | Drew University